**Diffuse Large B-cell Lymphoma Took Kit**

|  |  |
| --- | --- |
| Resource | Address |
| Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. *Blood*. 2005;106:1164-1174. | <https://pubmed.ncbi.nlm.nih.gov/15855278/> |
| Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. *J Clin Oncol*. 1998;16:2780-2795. | <https://pubmed.ncbi.nlm.nih.gov/9704731/> |
| Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin  lymphoma, including patients refractory to CAR T therapy. *Blood.* 2020;136(suppl 1):42-43. | <https://www.sciencedirect.com/science/article/pii/S0006497118696065> |
| Bartlett NL, Giri P, Budde E, et al. Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing Is tolerable and active in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B-NHL): Initial results from a phase I/II study. *Blood.* 2021;138(suppl 1):3573. | <https://ashpublications.org/blood/article/138/Supplement%201/3573/479734/Subcutaneous-SC-Administration-of-Mosunetuzumab?searchresult=1> |
| Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. *N Engl J Med*. 2022;386:629-639. | <https://pubmed.ncbi.nlm.nih.gov/34904798/> |
| Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. *J Clin Oncol*. 2022;40:481-491. | <https://pubmed.ncbi.nlm.nih.gov/34914545/> |
| Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol*. 2021;22:790-800. | <https://pubmed.ncbi.nlm.nih.gov/33989558/> |
| Dickinson M, Carlo-Stella C, Morschhauser F, et al. 2478 Glofitamab monotherapy provides durable responses after fixed-length dosing in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts). Presented at: American Society of Hematology annual meeting. 2021; New Orleans, LA. | <https://ash.confex.com/ash/2021/webprogram/Paper146845.html> |
| Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol*. 2005;23:4117-4126. | <https://pubmed.ncbi.nlm.nih.gov/15867204/> |
| Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol*. 2010;28:4184-4190. | <https://pubmed.ncbi.nlm.nih.gov/20660832/> |
| Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study. *Lancet*. 2021;398:1157-1169. | <https://pubmed.ncbi.nlm.nih.gov/34508654/> |
| Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. *Blood*. 2015;125:1394-1402. | <https://pubmed.ncbi.nlm.nih.gov/25573987/> |
| Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. *J Clin Oncol*. 2012;30:3452-3459. | <https://pubmed.ncbi.nlm.nih.gov/22851565/> |
| Kamdar M, et al. 91 Lisocabtagene Maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study. Presented at: American Society of Hematology annual meeting. 2021; New Orleans, LA. | <https://ash.confex.com/ash/2021/webprogram/Paper147913.html> |
| Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. *N Engl J Med*. 2022;386:640-654. | <https://pubmed.ncbi.nlm.nih.gov/34891224/> |
| Minson A, Dickinson M. Glofitamab CD20-TCB bispecific antibody. *Leuk Lymphoma*. 2021;62(13):3098-3108. | <https://pubmed.ncbi.nlm.nih.gov/34263696/> |
| National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 2.2022. | <https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf> |
| Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: A multicenter retrospective analysis. *Blood*. 2014;124:2354-2361. | <https://pubmed.ncbi.nlm.nih.gov/25161267/> |
| Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med*. 1995;333(23):1540-1545. | <https://pubmed.ncbi.nlm.nih.gov/7477169/> |
| Rosenwald A, Bens S, Advani R, et al. Prognostic significance of *MYC* rearrangement and translocation partner in diffuse large B-cell lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium. *J Clin Oncol*. 2019;37:3359-3368. | <https://pubmed.ncbi.nlm.nih.gov/31498031/> |
| Schuster S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood 2019;134(suppl 1):6. | <https://ashpublications.org/blood/article/134/Supplement_1/6/427814/Mosunetuzumab-Induces-Complete-Remissions-in-Poor> |
| Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. *J Clin Oncol*. 2020;38:155-165. | <https://pubmed.ncbi.nlm.nih.gov/31693429/> |
| Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B-NHL): Initial results from a phase I/II study. Presented at: American Society of Hematology annual meeting. 2021; New Orleans, LA. | <https://ash.confex.com/ash/2021/webprogram/Paper147937.html> |
| Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. *N Engl J Med*. 2022;386:351-363. | <https://pubmed.ncbi.nlm.nih.gov/34904799/> |
| van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD study. *J Clin Oncol*. 2017;35:544-551. | <https://pubmed.ncbi.nlm.nih.gov/28029326/> |
| Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. *J Clin Oncol*. 2017;35:3529-3537. | <https://pubmed.ncbi.nlm.nih.gov/28796588/> |
| Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. *Blood*. 2014;123:837-842. | <https://pubmed.ncbi.nlm.nih.gov/24264230/> |
| Zhu M, Olson K, Kirshner JR, et al. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies [published online ahead of print, 2022 Jan 7]. *Clin Transl Sci*. 2022;10.1111/cts.13212. | <https://pubmed.ncbi.nlm.nih.gov/34997701/> |